Source: Annual Congress 2010 - Pathology of lung cancer

Abstract

The past decade has seen an increasing interest in the dependence of the growth of lung cancer (LC) on angiogenesis [1]. We have performed association studies between a novels coding single nucleotide polymorphism (D104N) in endostatin, one of the most potent inhibitors of angiogenesis.
More recently, a COL18A1 gene polymorphism (D104N) was associated with increased risk for the prostate and breast carcinoma, which were attributed to a possible impairment in the protein function [2]. Since it is not known whether the D104N genotypes alter the risk of LC, this was the aim of this study.
We analysed 199 LC patients (median age: 64 years, range: 39-85; 144 men, 55 women; 157 Caucasians, 42 African-Brazilians) and 366 controls represented by blood donors (median age: 53 years, range 25-62; 198 men, 168 women; 318 Caucasians, 48 African-Brazilians) seen at the University Hospital -State University of Campinas.
Genomic DNA from peripheral blood of all individuals was analysed by the polymerase chain reaction (PCR) and restriction endonuclease digestion.
Controls‘ and patients´ samples were in Hardy-Weinberg equilibrium (X²= 1.96, P= 0.93; X²= 0.26, P= 0.96). Similar frequencies of the heterozygous variant genotype (104DN) were seen in patients and controls (7.04% versus 13.66%, P= 0.09). The homozygous variant genotype (104NN) was not found in study. Similar risks for the LC (OR= 0.47, 95% CI: 0.20-1.11) were seen in individuals with the 104DN and 104DD genotypes, after adjustment by age, gender and ethnical origin.
In conclusion, our results suggest that the D104N polymorphism of the COL18A1 gene may be an unimportant inherited determinant of the LC susceptibility.

Rating:

Share or cite this content

Citations should be made in the following way:
L. Zambon, H. Honma, G. Lourenço, I. Saad, R. Mussi, C. Lima (Brazil). D104N poluymorphism in endostatin, an angiogenesis inhibitor, in lung cancer susceptibility. Eur Respir J 2010; 36: Suppl. 54, 3263

Member's Comments

No comment yet.

Related content which might interest you: Novel anti-angiogenic pharmacotherapy strategies Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases Year: 2005 Tumor-related angiogenesis: role in tumour growth and metastasis formation Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases Year: 2005 Adipocyte-derived exosomes promote lung cancer metastasis byincreasing MMP9 activity via transferring MMP3 to lung cancer cells Source: International Congress 2017 – Basic research in lung cancer: a scientific potpourri from genetic alterations to immune cells Year: 2017 The biology of lung cancer Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=61 Year: 2001 Increased vascular-endothelial growth factor a (VEGF-A) expression and response to angiogenesis inhibitor erlotinib in non-small-cell lung cancer (NSCLC) – hint for a new predictive marker? Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology Year: 2007 Markers of angiogenesis in serum are correlating with disease progress in lung cancer Source: Annual Congress 2006 - Prognostic factors in lung cancer Year: 2006 Tissue inhibitors of metalloproteinase-2 C-303T and G-418C genetic polymorphisms are associated with an increased risk of non-small cell lung cancer in Taiwan Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008 The association of MMP-7 and MMP-13 genetic polymorphisms with susceptibility to non-small cell lung cancer in Taiwan Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008 Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer Source: Eur Respir J 2002; 19: 557-570 Year: 2002 A novel biologic classification of non-small cell lung cancer Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology Year: 2005 Diverse effects of PAI-1 proteins on lung and prostate cancer cell invasion Source: Annual Congress 2011 - Lung development and neoplasia Year: 2011 Proteinase inhibition regulates the anti-tumor activity of PAI-1 towards lung and prostate cancer cells Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011 Predicting activity of EGFR (epidermal growth factor receptor) inhibitors in diffuse bronchiolo-alveolar carcinoma or so-called pneumonic adenocarcinoma Source: Annual Congress 2006 - Bronchiolo-alveolar carcinoma Year: 2006 Association of polymorphism of the human nm23-H1 gene (NME1) with susceptibility to and severity of non-small cell lung cancer Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007 The effect of SDF-1/CXCR4 on expression of VEGF and MMP-9 in small cell lung cancer Source: Annual Congress 2012 - New aspects of lung cancer biology Year: 2012 Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation Source: Eur Respir J 2011; 37: 624-631 Year: 2011 The effect of matrix metalloproteinase-9 and vascular endothelial growth factor expression on survival of non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 324s Year: 2005 ABCG2 is determinant to SN-38 resistance in non-small cell lung cancer Source: Annual Congress 2005 - Prognostic factors in lung cancer Year: 2005 Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer Source: Eur Respir J 2007; 30: 627-632 Year: 2007 Efficacy of Afatinib, Erlotinib, and Gefitinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients with brain metastasis: a network meta-analysis Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018